Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | APP | P05067 | 5/20 | 0.79 |
| ▸ | CTSD | P07339 | 1/20 | 0.79 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363616 | 1.00 | BACE1 (1.00) | BACE1APPCTSDBACE2CYP2D6 | |
| SCHEMBL361507 | 0.88 | BACE1 (1.00) | BACE1APPCTSDBACE2CYP2D6 | |
| SCHEMBL360791 | 0.88 | BACE1 (1.00) | BACE1APPCTSDBACE2CYP2D6 | |
| SCHEMBL16390577 | 0.88 | BACE1 (0.78) | BACE1APPCTSDBACE2CYP2D6 | |
| Hydrochloric Acid SCHEMBL361960 | 0.87 | BACE1 (0.98) | BACE1APPCTSDBACE2CYP2D6 | |
| SCHEMBL10270334 | 0.86 | BACE1 (1.00) | BACE1APPBACE2CYP2D6CYP3A4 | |
| SCHEMBL15611434 | 0.86 | BACE1 (1.00) | BACE1APPBACE2CYP2D6CYP3A4 | |
| SCHEMBL16405068 | 0.82 | BACE1 (0.70) | BACE1APPCTSD | |
| SCHEMBL362026 | 0.81 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL361326 | 0.81 | BACE1 (1.00) | BACE1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088084-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | HOLZER PHILIPP (CH) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088084-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885APP 94/4885CTSD 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.